Cartesian Therapeutics (RNAC) announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on December 12, 2028. The options have a ten-year term.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics files to sell 11.39M shares of common stock for holders
- Cartesian Therapeutics files to sell 6.25M shares of common stock for holders
- Cartesian Therapeutics files $400M mixed securities shelf
- Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Cartesian Therapeutics Reports Promising Phase 2b Trial Results